June 25, 2015

Drug Combo Offers Hope for People with Advanced Melanoma

By msequeira

Monte Shaheen, MD, is among the authors of a paper that describes the new drug combination tested in a clinical trial. Dr. Shaheen oversaw the clinical trial at UNM Cancer Center. Once it has spread, melanoma is difficult to treat and only about 10 percent of people respond to chemotherapy. The new drug combination has a response rate greater than 70 percent and, because the drugs activate the immune system, the effects last a long time. Read more about the clinical research in the press release.

View Dr. Shaheen's interview with Nikki Ibarra, KOB-TV (below)  and KOAT-TV's story about Dr. Shaheen's work.

Dr. Shaheen also talked to Adam Atchison on KRQE's "This Morning"

Tags: advanced melanoma, General Skin Cancer, In the News Archive, Melanoma, Recurrent Melanoma, Skin Cancer, stage 3 melanoma, Stage III Melanoma, Stage IV Melanoma